Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

U.K. Use Of J&J's Cisapride Halted Pending 2001 Ruling On Status In EU

  • News

Executive Summary

The U.K.' s Medicines Control Agency is withdrawing Johnson & Johnson's cisapride from the market, pending a decision on the drug's status in the EU, expected in 2001.

You may also be interested in...



Canada Implements New Recall/Disclosure Policy

Health Canada finalizes guideline on its new powers to order recalls or disclose information related to serious risks of injuries for drugs, but says it will develop more details on how it will use the authorities.

J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use

Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).

J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use

Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS036395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By